论文部分内容阅读
目的:探讨不同剂量阿托伐他汀钙短期应用对冠状动脉粥样硬化性心脏病患者血清胆红素水平的影响。方法:按照详细的纳入及排除标准的筛选共计264例冠状动脉粥样硬化性心脏病患者入选,分为20 mg和40 mg治疗剂量组,观察患者用药前后胆红素水平的变化水平的改变。结果:与服药前的相比,服用阿托伐他汀钙40 mg和20 mg的患者血清总胆红素、直接胆红素水平均呈显著性上升(P<0.05),而间接胆红素水平差异无显著性。服药1个月后,40 mg组患者血清总胆红素、直接胆红素水平升高较20 mg组更显著(P<0.05),但两组间接胆红素水平差异没有显著性。总胆红素变化率与患者胆固醇水平呈显著相关性,其20mg组为0.419,40 mg组为0.634(P<0.001)。结论:阿托伐他汀钙治疗冠状动脉粥样硬化性心脏病患者可导致其血清总胆红素和直接胆红素水平升高,且高剂量较低剂量对总胆红素和直接胆红素的影响更明显。
Objective: To investigate the effect of different doses of atorvastatin on serum bilirubin level in patients with coronary atherosclerotic heart disease. Methods: According to the detailed inclusion and exclusion criteria, a total of 264 patients with coronary atherosclerotic heart disease were enrolled. The patients were divided into 20 mg and 40 mg treatment groups, and the changes of bilirubin levels before and after treatment were observed. Results: Serum total bilirubin and direct bilirubin levels were significantly increased (P <0.05) in patients taking atorvastatin 40 mg and 20 mg compared with those before medication, while indirect bilirubin No significant difference. One month after taking medicine, the level of serum total bilirubin and direct bilirubin in 40 mg group was more significant than that in 20 mg group (P <0.05), but there was no significant difference between the two groups in indirect bilirubin level. The change of total bilirubin was significantly correlated with the level of cholesterol in patients with 0.4 mg in 20 mg group and 0.634 in 40 mg group (P <0.001). Conclusions: Atorvastatin calcium treatment of patients with coronary atherosclerotic heart disease can lead to elevated levels of serum total bilirubin and direct bilirubin, and high doses of lower doses of total bilirubin and direct bilirubin The effect is more obvious.